^
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Active, not recruiting, Guangzhou Bio-gene Technology Co., Ltd | Recruiting --> Active, not recruiting | Initiation date: Aug 2023 --> May 2023
Enrollment closed • Trial initiation date
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Phase classification: P=N/A --> P1/2
Phase classification
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
New P1/2 trial • New trial
|
CD7 (CD7 Molecule)
|
CD7 CAR-T